Target Price | $35.00 |
Price | $34.78 |
Potential |
0.63%
register free of charge
|
Number of Estimates | 2 |
2 Analysts have issued a price target HashiCorp 2026 .
The average HashiCorp target price is $35.00.
This is
0.63%
register free of charge
$35.00
0.63%
register free of charge
$35.00
0.63%
register free of charge
|
|
A rating was issued by 5 analysts: 0 Analysts recommend HashiCorp to buy, 4 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the HashiCorp stock has an average upside potential 2026 of
0.63%
register free of charge
|
Jan '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 583.14 | 676.86 |
22.54% | 16.07% | |
EBITDA Margin | -41.89% | 0.98% |
31.22% | 102.34% |
3 Analysts have issued a sales forecast HashiCorp 2025 . The average HashiCorp sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an HashiCorp EBITDA forecast 2025. The average HashiCorp EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
Jan '24 |
2025 Estimates |
|
---|---|---|
EV/Sales | 8.52 |
Analyst | Rating | Action | Date |
---|---|---|---|
JMP Securities |
Locked
➜
Locked
|
Locked | Dec 16 2024 |
JMP Securities |
Locked
➜
Locked
|
Locked | Sep 16 2024 |
Citigroup |
Locked
➜
Locked
|
Locked | Sep 03 2024 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Aug 30 2024 |
Analyst Rating | Date |
---|---|
Locked
JMP Securities:
Locked
➜
Locked
|
Dec 16 2024 |
Locked
JMP Securities:
Locked
➜
Locked
|
Sep 16 2024 |
Locked
Citigroup:
Locked
➜
Locked
|
Sep 03 2024 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Aug 30 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.